Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Regenx BioSciences has received $2.8m grant from National Institutes of Health (NIH) through the National Eye Institute (NEI) for its novel program using NAV technology for the treatment of X-Linked Retinitis Pigmentosa (RP or X-Linked RP).
Subscribe to our email newsletter
According to preclinical studies across multiple animal models, the NAV technology, and in particular NAV rAAV8 vector, targets the photoreceptor layer to preserve vision using gene delivery approaches.
The company holds exclusive rights to a portfolio of over 100 patents and patent applications pertaining to its NAV technology and related applications.
Regenx president and CEO Kenneth Mills said they are pleased to have received this funding and support from NEI and recognize the critical importance of accelerating early stage development into meaningful treatments for inherited and acquired retinal diseases.